Search
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain o...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSJG-136
go.drugbank.com/drugs/DB11965InvestigationalSJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes,...
Categories: P-glycoprotein substratesBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesPonesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLorvotuzumab mertansine
go.drugbank.com/drugs/DB12089InvestigationalLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSecoisolariciresinol
go.drugbank.com/drugs/DB12179InvestigationalSecoisolariciresinol has been used in trials studying the prevention of Breast Cancer.
Categories: P-glycoprotein inhibitorsFexinidazole
go.drugbank.com/drugs/DB12265ApprovedHuman African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focuss...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesEpofolate
go.drugbank.com/drugs/DB12266InvestigationalEpofolate has been used in trials studying the treatment of Advanced Solid Tumors. Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigationalAducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab. Aducanumab is a recombinant antibody derived from patients with slow ...
1,2-Benzodiazepine
go.drugbank.com/drugs/DB12537ApprovedInvestigationalWithdrawnBenzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates